Cargando…
Transient Arterial Hypertension Induced by Gonadotropin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
Background: Gonadotropin-releasing hormone agonists (GnRHa) are a safe and effective treatment for precocious puberty. Triptorelin is one of the long lasting GnRHa, which reversibly suppresses the pituitary-gonadal axis. Triptorelin-induced hypertension (HTN) has rarely been reported in the literatu...
Autores principales: | Sifaki, Loukia, Cachat, Francois, Theintz, Gerald, Chehade, Hassib |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433848/ https://www.ncbi.nlm.nih.gov/pubmed/30941336 http://dx.doi.org/10.3389/fped.2019.00074 |
Ejemplares similares
-
Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States
por: Popovic, Jadranka, et al.
Publicado: (2022) -
SAT-304 Unexplained Asymptomatic Hyperestrogenism in Central Precocious Puberty Patient Treated with Gonadotropin Releasing Hormone Agonist
por: Kim, Dae Hyun, et al.
Publicado: (2019) -
Gonadotropin-releasing Hormone Stimulation Test for Precocious Puberty
por: Kim, Han Kyul, et al.
Publicado: (2011) -
Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
por: Kim, Hye Ryun, et al.
Publicado: (2017) -
The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty
por: Yoon, Jong Wan, et al.
Publicado: (2017)